US 9567587
Antisense modulation of GCCR expression
granted A61KA61K31/7088A61K31/7115
Quick answer
US patent 9567587 (Antisense modulation of GCCR expression) held by Ionis Pharmaceuticals, Inc. expires Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue Feb 14 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 09 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 24
- CPC classes
- A61K, A61K31/7088, A61K31/7115, A61K31/712, A61K31/7125